IRADIMED (IRMD) CEO trust sells 7,500 shares under 10b5-1 plan
Rhea-AI Filing Summary
IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Small CEO‑linked trust sales under a 10b5‑1 plan look routine.
The filing shows the Phillip Susi 2008 Dynasty Trust sold 7,500 IRADIMED CORP common shares in two open‑market trades around $100 per share. After these sales, the trust still holds 2,247,500 shares, indicating only a modest reduction in this position.
The trades were executed pursuant to a pre‑established Rule 10b5‑1 trading plan adopted on November 5, 2025, suggesting they were scheduled in advance rather than timed opportunistically. The reporting person also disclaims full beneficial ownership, limiting the economic signal for investors.
Because the sale volume is small relative to the remaining reported indirect holdings and occurs under a trading plan, this activity typically reads as routine portfolio management rather than a major change in insider sentiment. Subsequent insider reports may further clarify any ongoing selling pattern.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,500 | $100.11 | $250K |
| Sale | Common Stock | 5,000 | $100.04 | $500K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
